Harrow, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $862.41M
  • PE -49
  • Debt $262.74M
  • Cash $47.25M
  • EV $1.08B
  • FCF -$23.80M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$17.48M
EBIT$8.82M
ROE-25%
ROA2%
FCF-$23.80M
Equity$69.65M
Growth Stability-500%
PE-49.33
PB12.38
P/FCF-36.24
P/S4.32
Price/Cash0.05
Debt/Equity3.77
Debt/FCF-11.04
Net Margins-9%
Gross Margins75%
Op. Margins4%
Earnings CAGR-0%
Sales Growth YoY84%
Sales Growth QoQ36%
Sales CAGR29%
FCF CAGR1%
Equity CAGR34%
Earnings Stability0
Earnings Growth YoY-174%
Earnings Growth QoQ-261%
Sales CAGR 5Y35%
FCF CAGR 5Y7%
Equity CAGR 5Y36%
Earnings CAGR 3Y39%
Sales CAGR 3Y39%
FCF CAGR 3Y21%
Equity CAGR 3Y197%
Market Cap$862.41M
Revenue$199.61M
Assets$388.97M
Total Debt$262.74M
Cash$47.25M
Shares Outstanding35.62M
EV1.08B
Earnings Score6%
Moat Score11%
Safety Score26%
Final Score14%
Working Capital98.31M
Current Ratio2.08
Gross Profit$150.37M
Shares Growth 3y13%
Equity Growth QoQ20%
Equity Growth YoY-2%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.

SEC Filings

Direct access to Harrow, Inc. (HROW) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Harrow, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Harrow, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%
Stability 0%
loading chart...

Harrow, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Harrow, Inc..

= -$253M
012345678910TV
fcf-$24M-$24M-$24M-$24M-$25M-$25M-$25M-$25M-$26M-$26M-$26M-$261M
DCF-$22M-$20M-$18M-$17M-$15M-$14M-$13M-$12M-$11M-$10M-$101M
Value-$253M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-164%-96%-45%35%-0%-7%-25%-16%-19%-9%-9%
ROA--58%-51%30%-0%1%2%1%0%2%2%
ROE--297%-458%59%-0%-13%-164%-51%-34%-25%-25%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--0.92-2.45-24.04-3.42-11.5431.26-170.15103.66-11.04-11.04
Debt over Equity-0.628.971.050.060.839.135.53.493.773.77
Growth Stability------408%-500%----500%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-105%34%55%24%-4%48%22%47%53%35%
Earnings YoY growth-20%-37%-222%-101%3K%440%-24%73%-28%-
Equity YoY growth--564%-59%847%12%-2%-58%145%156%-2%36%
FCF YoY growth--64%121%-89%-52%279%-268%-127%-367%-1K%7%